🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Targeting Sleep and the Glymphatic Pathway to Improve Stroke Rehabilitation Outcomes: Joyce Lee-Iannotti, MD, FAAN, FAASM neurologylive.com/view/targeting… via NeurologyLive®

You're invited to TSF's Research Update & Award Ceremony in BCN 🇪🇸 during ECTRIMS. Join us for research updates, recognition of outstanding achievements in the field & networking with a community dedicated to neuroscience. To reserve tickets, visit eventbrite.com/e/entradas-202…

#BREAKING: The U.S. FDA has approved an updated label for donanemab (Kisulna; Eli Lilly and Company) to now include a new recommended titration dosing schedule, which may lead to lowered risk of amyloid-related imaging abnormalities #ARIA. Our coverage: neurologylive.com/view/fda-appro…

Recently, the FDA has approved the use of the Exablate Neuro platform for staged bilateral pallidothalamic tractotomy in patients with advanced #Parkinsons disease. #MovementDisorders @Insightec Read More: hubs.li/Q03wsQCL0

We lured our neuroradiologist out of the darkroom and built a consensus MRI protocol for MS, aligned with the 2024 McDonald Criteria! 🚀 Smarter scans, fewer sequences, no 3T? ✅ Cornish hills behind us, progress ahead. 🌄🧠 #MS #MRI #McDonaldCriteria2024 #MultipleSclerosis

Registration is open for the “Updates in Stroke for EMS Providers” event on July 17. This complimentary event aims to help first responders learn how to identify #stroke and improve patients’ survival. Register now: zoom.us/webinar/regist…

Francois Bethoux's not-so-secret secret: an interest in #medicine and the #arts. A highlight of his 10 years as #EIC of IJMSC is an initiative with MS Assoc. of America that centers people with #MultipleSclerosis. neurologylive.com/view/francois-…

At #ATMRD25, David Shprecher, DO, MSci, FAAN, of Banner Health, discussed considerations for distinguishing atypical Parkinsonian disorders early, and planning care around their complex symptomatology. Parkinson & Movement Disorder Alliance Watch Now: hubs.li/Q03wsVHd0

A recently study of patients with large vessel occlusion stroke revealed that a 0° head position prior to endovascular thrombectomy was safe and the most optimal positioning to prevent clinical worsening. JAMA Neurology READ MORE: hubs.li/Q03wsXL60

🙏 We would like to thank NeurologyLive® for their comprehensive coverage of the new long-term open-label extension data from our phase 2 #EMPhASIS trial in relapsing-remitting #MultipleSclerosis (#RRMS). 🧠 The article highlights encouraging findings: over 90% of patients

Barrow #sleep & stroke #neurologist Dr. Joyce Lee-Iannotti gave a presentation at #SLEEP2025, in which she discussed the role of the #glymphaticsystem in #stroke pathophysiology & recovery. Learn more in her interview with NeurologyLive®: bar.rw/4645oeb

Newly published data from the CORE-VNS study showed sustained reductions in generalized tonic-clonic seizures among patients with drug-resistant #epilepsy following treatment with vagus nerve system therapy. @LivaNova Read More: hubs.ly/Q03wKGLr0

🧠 Sleep and stroke recovery: more connected than you think. In our latest Mind Moments episode, Joyce Lee-Iannotti, MD, PhD, of BarrowNeurological joins us to discuss the glymphatic system—a sleep-activated clearance system—and how it could reshape stroke prevention and

In a recent interview held at #SLEEP2025, Bryce Mander, of UC Irvine, explored how analyzing specific sleep oscillations may uncover early neurodegenerative changes and guide future therapeutic targets. 💤🌙 American Academy of Sleep Medicine 👉 WATCH NOW: hubs.ly/Q03wKP2q0

New data from an indirect treatment comparison of the Vivacity-MG3 study presented at #EAN2025 revealed consistent and sustained efficacy with nipocalimab, an FDA-approved treatment for generalized #MyastheniaGravis, compared with other approved FcRn blockers. Johnson & Johnson Read

Takeda’s TAK-861, now called oveporexton, showed strong phase 2b results in narcolepsy type 1. 💤 Across 8 weeks, patients had significant improvements in EDS and cataplexy at all doses vs placebo. Full results in NEJM. 🔗hubs.li/Q03wWpNB0

💤 Missed this week’s #MindMoments? We talked with Dr. Joyce Lee-Iannotti about: • Glymphatics 101 • Stroke recovery insights • Sleep-driven prevention strategies Listen now: hubs.li/Q03wWwPh0

At the 2025 ATMRD Congress, hosted by Parkinson & Movement Disorder Alliance, Molly Abbott, of King's College London, highlighted significant gender differences in anxiety, depression, quality of life, and social support among patients with PD undergoing deep brain stimulation. 📽️neurologylive.com/view/gender-di…

Ambroxol showed safety over 52 weeks in patients with Parkinson disease dementia 🧠 🧪 No clear cognitive gains, but stabilized neuropsychiatric symptoms + GFAP levels. More on this phase 2 placebo-controlled study: 🔗hubs.li/Q03wWDCK0

🧠 Label update alert: The FDA approved a new titration schedule for donanemab (Kisunla) for early Alzheimer disease to help reduce amyloid-related imaging abnormalities (ARIA). Full story: 🔗hubs.li/Q03wWCgX0